The weekly litigation news digest is live. Subscribe now

IP Verse

Sacubitril-Valsartan Dosage Regimen For Treating Heart Failure - EP3294283

The patent EP3294283 was granted to Novartis on Mar 8, 2023. The application was filed on May 9, 2016 under application number EP16722388A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3294283

NOVARTIS
Application Number
EP16722388A
Filing Date
May 9, 2016
Status
Granted And Under Opposition
Feb 3, 2023
Publication Date
Mar 8, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Treatment of heart failure in a human patient that prevents the onset of a disease characterized and / or manifested by atrial enlargement and/or remodeling. The treatment comprises administering to a patient in need thereof a twice-daily target dose of an Angiotensin Receptor Neprilysin inhibitor (ARNi) or of a combination of an Angiotensin Receptor Blocker (ARB) with a Neutral Endopeptidase inhibitor (NEPi) or with a NEPi pro-drug, wherein said target dose is reached after a titration with an initial lower twice-daily dose of said ARNI increasing to the twice daily target dose from 5 to 8 weeks.

Patent Family

Patent Family

Patent Oppositions (16)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status
BULLE DRDec 8, 2023KUTZENBERGER WOLFF & PARTNERADMISSIBLE
KRKADec 8, 2023HOFFMANN EITLEADMISSIBLE
ZENTIVADec 8, 2023GREINERADMISSIBLE
ALFRED E TIEFENBACHERDec 7, 2023HAMM & WITTKOPPADMISSIBLE
BETAPHARM ARZNEIMITTELDec 7, 2023HAMM & WITTKOPPADMISSIBLE
GENERICS UKDec 7, 2023ELKINGTON AND FIFEADMISSIBLE
POLPHARMADec 7, 2023HAMM & WITTKOPPADMISSIBLE
SANOVEL IIAC SAN VE TICDec 7, 2023KRAUS & LEDERERADMISSIBLE
SANOVEL IIAC SAN VE TICDec 7, 2023KRAUS & LEDERER PARTGMBBADMISSIBLE
STRAWMANDec 7, 2023PINSENT MASONSADMISSIBLE
SYNTHONDec 7, 2023HAMM & WITTKOPPADMISSIBLE
TEVA PHARMACEUTICALSDec 7, 2023D YOUNGADMISSIBLE
HOFFMANN EITLEDec 4, 2023HOFFMANN EITLEWITHDRAWN
DR SCHONNov 30, 2023DR SCHONADMISSIBLE
CAMULONNov 23, 2023REDDIE & GROSEADMISSIBLE
EGISOct 9, 2023STOLMAR & PARTNERADMISSIBLE

Patent Citations (11) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONEP0443983
DESCRIPTIONUS5217996
DESCRIPTIONUS5399578
DESCRIPTIONWO03059345
DESCRIPTIONWO2007056546
DESCRIPTIONWO2009061713
DESCRIPTIONWO2014029848
OPPOSITIONWO03059345
OPPOSITIONWO2014029848
OPPOSITIONWO2015030711
OPPOSITIONWO2016181284

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents